Long‐term benefits of darifenacin treatment for patient quality of life: Results from a 2‐year extension study

Overactive bladder (OAB), a chronic condition requiring long‐term management, is associated with substantial impact on health‐related quality of life (HRQoL). The short‐term benefits of antimuscarinic drug treatment are well known. Here we investigate the impact on HRQoL of long‐term treatment with the M3‐selective muscarinic receptor antagonist darifenacin over 2 years.

[1]  C. Kelleher,et al.  Clinical relevance of health‐related quality of life outcomes with darifenacin , 2008, BJU international.

[2]  T. Wilt,et al.  Systematic Review: Randomized, Controlled Trials of Nonsurgical Treatments for Urinary Incontinence in Women , 2008, Annals of Internal Medicine.

[3]  M. Elhilali,et al.  Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study , 2007, Current medical research and opinion.

[4]  S. Bolge,et al.  Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder , 2007, Current medical research and opinion.

[5]  N. Zinner.  Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder , 2007, Expert opinion on pharmacotherapy.

[6]  C. Kelleher,et al.  Redefining response in overactive bladder syndrome , 2007, BJU international.

[7]  K. Coyne,et al.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. , 2006, European urology.

[8]  W. Steers,et al.  Long‐term treatment with darifenacin for overactive bladder: results of a 2‐year, open‐label extension study , 2006, BJU international.

[9]  I. Hussain,et al.  Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. , 2006, Urology.

[10]  Z. Gabriel,et al.  The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. , 2006, Urology.

[11]  P. Abrams,et al.  A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder , 2005, BJU international.

[12]  C. Kelleher,et al.  228The emotional burden of overactive bladder (OAB) symptoms on sufferers , 2005 .

[13]  W. Steers,et al.  An investigation of dose titration with darifenacin, an M3‐selective receptor antagonist , 2005, BJU international.

[14]  C. Kelleher,et al.  How much is enough and who says so? , 2004, BJOG : an international journal of obstetrics and gynaecology.

[15]  F. Haab,et al.  Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. , 2004, European urology.

[16]  K. Andersson.  Antimuscarinics for treatment of overactive bladder , 2004, The Lancet Neurology.

[17]  C. Kelleher,et al.  Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder , 2003, Quality of Life Research.

[18]  W. Stewart,et al.  Prevalence and burden of overactive bladder in the United States , 2003, World Journal of Urology.

[19]  C. Kelleher.  Economic and Social Impact of OAB , 2002 .

[20]  Magnus Fall,et al.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. , 2003, Urology.

[21]  R. Lipton,et al.  Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. , 2001, Urology.

[22]  C. Kelleher,et al.  Overactive bladder significantly affects quality of life. , 2000, The American journal of managed care.

[23]  L. Cardozo,et al.  A new questionnaire to assess the quality of life of urinary incontinent women , 1997, British journal of obstetrics and gynaecology.